Arbutus Biopharma (NASDAQ:ABUS) Upgraded by StockNews.com to “Hold” Rating
Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday. Other equities analysts have also issued reports about the company. JMP Securities boosted their price target on Arbutus Biopharma to $5.00 and gave the company a […]
Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday. Other equities analysts have also issued reports about the company. JMP Securities boosted their price target on Arbutus Biopharma to $5.00 and gave the company a […]
